NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to ...
Platform-based approaches for gene-editing therapies could markedly improve development efficiency, reduce costs and increase access for patients with rare diseases. Although gene editing has shown ...
Cibus, Inc. announced significant advancements in its gene editing technology, particularly the establishment of production standards for its proprietary RTDS gene editing system, which enables the ...
Prime editing installs precise edits into the genome with minimal unwanted byproducts, but low and variable editing efficiencies have complicated application of the approach to high-throughput ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results